A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans
Jack Alistair Sargeant (Sargeant JA), Joseph Henson (Henson J), James Adam King (King JA), Thomas Yates (Yates T), Kamlesh Khunti (Khunti K), Melanie Jane Davies (Davies MJ)
Endocrinol Metab. 2019;34(3):247-262.   Published online 2019 Sep 26     DOI: https://doi.org/10.3803/EnM.2019.34.3.247
Citations to this article as recorded by Crossref logo
Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis
Sabine Kahl, Jennifer Pützer, Michael Roden
Seminars in Liver Disease.2022; 42(01): 048.     CrossRef
Effect of Empagliflozin Versus Placebo on Body Fluid Balance in Patients With Acute Myocardial Infarction and Type 2 Diabetes Mellitus: Subgroup Analysis of the EMBODY Trial
Yu Hoshika, Yoshiaki Kubota, Kosuke Mozawa, Shuhei Tara, Yukichi Tokita, Kenji Yodogawa, Yu-Ki Iwasaki, Takeshi Yamamoto, Hitoshi Takano, Yayoi Tsukada, Kuniya Asai, Masaaki Miyamoto, Yasushi Miyauchi, Eitaro Kodani, Mitsunori Maruyama, Jun Tanabe, Wataru
Journal of Cardiac Failure.2022; 28(1): 56.     CrossRef
Effect of GLP-1 receptor agonist, liraglutide, on muscle in spontaneously diabetic torii fatty rats
Shohei Yamada, Yuji Ogura, Kazuho Inoue, Jun Tanabe, Takeshi Sugaya, Keiichi Ohata, Yoshio Nagai, Yasunori Natsuki, Seiko Hoshino, Shiika Watanabe, Daisuke Ichikawa, Kenjiro Kimura, Yugo Shibagaki, Atsuko Kamijo-Ikemori
Molecular and Cellular Endocrinology.2022; 539: 111472.     CrossRef
Exendin-4 alleviates steatosis in an in vitro cell model by lowering FABP1 and FOXA1 expression via the Wnt/-catenin signaling pathway
Olfa Khalifa, Neyla S. AL-Akl, Khaoula Errafii, Abdelilah Arredouani
Scientific Reports.2022;[Epub]     CrossRef
Body composition changes at 12 months following different surgical weight loss interventions in adults with obesity: A systematic review and meta‐analysis of randomized control trials
Amy Sylivris, Jakub Mesinovic, David Scott, Paul Jansons
Obesity Reviews.2022;[Epub]     CrossRef
Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study
Kohei Kaku, Kazuhiro Yamamoto, Yumiko Fukushima, Hristo Lliev, Atsutaka Yasui
Expert Opinion on Drug Safety.2022; : 1.     CrossRef
Safety and effectiveness of empagliflozin according to body mass index in Japanese patients with type 2 diabetes: a subgroup analysis of a 3-year post-marketing surveillance study
Kohei Kaku, Kazuhiro Yamamoto, Yumiko Fukushima, Seiko Mizuno, Daisuke Nitta
Expert Opinion on Drug Safety.2022; : 1.     CrossRef
An overview of anamorelin as a treatment option for cancer-associated anorexia and cachexia
Guilherme Wesley Peixoto Da Fonseca, Stephan von Haehling
Expert Opinion on Pharmacotherapy.2021; 22(7): 889.     CrossRef
Liraglutide Does Not Adversely Impact Fat‐Free Mass Loss
Andrew Grannell, William P. Martin, Babak Dehestani, Werd Al‐Najim, John C. Murphy, Carel W. Roux
Obesity.2021; 29(3): 529.     CrossRef
Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium–glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabet
Daisuke Yabe, Kosuke Shiki, Keiko Suzaki, Thomas Meinicke, Yutaro Kotobuki, Kenichiro Nishida, Douglas Clark, Atsutaka Yasui, Yutaka Seino
BMJ Open.2021; 11(4): e045844.     CrossRef
Cancer Risk in Normal Weight Individuals with Metabolic Obesity: A Narrative Review
Bethina Liu, Hugh E. Giffney, Rhonda S. Arthur, Thomas E. Rohan, Andrew J. Dannenberg
Cancer Prevention Research.2021; 14(5): 509.     CrossRef
Comprehensive analysis of LncRNAs expression profiles in an in vitro model of steatosis treated with Exendin-4
Khaoula Errafii, Neyla S. Al-Akl, Olfa Khalifa, Abdelilah Arredouani
Journal of Translational Medicine.2021;[Epub]     CrossRef
Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus
Vaneza Lira W. Wolf, Ikaro Breder, Luiz Sérgio F. de Carvalho, Alexandre A. S. Soares, Riobaldo M. Cintra, Joaquim Barreto, Daniel B. Munhoz, Sheila T. Kimura-Medorima, Wilson Nadruz, Gil Guerra-Júnior, Thiago Quinaglia, Elza Muscelli, Andrei C. Sposito
Nutrition & Diabetes.2021;[Epub]     CrossRef
Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors
Marc Evans, Angharad R. Morgan, Zaheer Yousef, Gethin Ellis, Umesh Dashora, Dipesh C. Patel, Pam Brown, Wasim Hanif, Johnathan N. Townend, Naresh Kanumilli, Jim Moore, John P. H. Wilding, Stephen C. Bain
Drugs.2021; 81(11): 1243.     CrossRef
Glucose-lowering Drugs and Hospitalization for Heart Failure: A Systematic Review and Additive-effects Network Meta-analysis With More Than 500 000 Patient-years
Riobaldo M Cintra, Ana Claudia Nogueira, Isabella Bonilha, Beatriz M Luchiari, Otavio R Coelho-Filho, Otavio R Coelho, Pedro Schwartzmann, Elza Muscellie, Wilson Nadruz, Luiz Sergio F Carvalho, Andrei C Sposito
The Journal of Clinical Endocrinology & Metabolism.2021; 106(10): 3060.     CrossRef
Physical activity and exercise in the management of type 2 diabetes: where to start?
Deirdre Harrington, Joe Henson
Practical Diabetes.2021; 38(5): 35.     CrossRef
Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes
New England Journal of Medicine.2021; 385(22): 2105.     CrossRef
Effects of Antidiabetic Drugs on Muscle Mass in Type 2 Diabetes Mellitus
Satoshi Ida, Ryutaro Kaneko, Kanako Imataka, Kaoru Okubo, Yoshitaka Shirakura, Kentaro Azuma, Ryoko Fujiwara, Kazuya Murata
Current Diabetes Reviews.2021; 17(3): 293.     CrossRef
Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: A randomized controlled study
Hirotatsu Nakaguchi, Yoshinobu Kondo, Mayu Kyohara, Hiromi Konishi, Koji Oiwa, Yasuo Terauchi
Journal of Diabetes Investigation.2020; 11(6): 1542.     CrossRef
Sodium Glucose Co-Transporter 2 Inhibition Does Not Favorably Modify the Physiological Responses to Dietary Counselling in Diabetes-Free, Sedentary Overweight and Obese Adult Humans
Shane P.P. Ryan, Alissa A. Newman, Jessie R. Wilburn, Lauren D. Rhoades, S. Raj J. Trikha, Ellen C. Godwin, Hayden M. Schoenberg, Micah L. Battson, Taylor R. Ewell, Gary J. Luckasen, Laurie M. Biela, Christopher L. Melby, Christopher Bell
Nutrients.2020; 12(2): 510.     CrossRef
GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report
Eva W. Iepsen, Christian T. Have, Simon Veedfald, Sten Madsbad, Jens J. Holst, Niels Grarup, Oluf Pedersen, Ivan Brandslund, Jens-Christian Holm, Torben Hansen, Signe S. Torekov
Cell Reports Medicine.2020; 1(1): 100006.     CrossRef
Glucagon‐like peptide 1 infusions overcome anabolic resistance to feeding in older human muscle
Haitham Abdulla, Bethan E. Phillips, Daniel J. Wilkinson, Marie Limb, Tereza Jandova, Joseph J. Bass, Debbie Rankin, Jessica Cegielski, Mariwan Sayda, Hannah Crossland, John P. Williams, Kenneth Smith, Iskandar Idris, Philip J. Atherton
Aging Cell.2020;[Epub]     CrossRef